BioMarin's Vimizim gets FDA nod

|About: BioMarin Pharmaceutical ... (BMRN)|By:, SA News Editor

BioMarin's (BMRN -0.5%) Vimizim becomes the 2nd treatment for Morquio A syndrome approved by the FDA this week. The nod isn't a surprise after nearly getting a near-unanimous thumbs up at the Ad Com two months ago.